Treatment of status epilepticus

Expert Review of Neurotherapeutics

Volumn 8, Issue 12, 2008, Pages 1817-1827

  Miller, Laura C ^a   Drislane, Frank W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiepileptic drug; Convulsive status epilepticus; EEG; Electroencephalogram; Nonconvulsive status epilepticus; Status epilepticus; Treatment

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; KETAMINE; LIDOCAINE; LITHIUM; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; PARALDEHYDE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; STEROID; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VIGABATRIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DYSTONIA; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HEART DISEASE; HEART FAILURE; HEMISPHERECTOMY; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER DISEASE; LOADING DRUG DOSE; METABOLIC ACIDOSIS; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PATIENT MONITORING; REVIEW; RHABDOMYOLYSIS; TREMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICONVULSANTS; HUMANS; STATUS EPILEPTICUS;

EID: 57749175530     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.12.1817     Document Type: Review

References (101)

1. Commission on epidemiology and prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 34, 592-596 (1993).
2. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 40, 120-122 (1999).
3. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 40(5 Suppl. 2), 9-13 (1990).
4. DeLorenzo RJ, Hauser WA, Towne AR et al. A prospective population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 46, 1029-1035 (1996).
5. Barry E, Hauser WA. Status epilepticus: the interaction of epilepsy and acute brain disease. Neurology 43, 1473-1478 (1993).
6. Devinsky O, Kelley K, Porter RJ, Theodore WH. Clinical and electroencephalographic features of simple partial seizures. Neurology 38, 1347-1352 (1998).
7. Kaplan PW. Clinical presentations of nonconvulsive status epilepticus. In: Status Epilepticus - a Clinical Perspective. Drislane FW (Ed.). Humana Press, NJ, USA (2005).
8. Devinsky O, Thacker K. Nonepileptic seizures. Neurologic Clinics 13, 299-319 (1995).
9. Krumholz A. Nonepileptic seizures: diagnosis and management. Neurology 53(Suppl. 2), 76-83 (1999).
10. Dworetzky BA, Bromfield EB. Differential diagnosis of status epilepticus. In: Status Epilepticus - a Clinical Perspective. Drislane FW (Ed.). Humana Press, NJ, USA (2005).
11. Howell SJL, Owen L, Chadwick DW. Pseudostatus epilepticus. Q. J. Med. 71, 507-519 (1989).
12. Aminoff MF, Simon RP. Status epilepticus: causes, clinical features, and consequences in 98 patients. Am. J. Med. 69, 657-666 (1980).
13. Shorvon SS. Prognosis and outcome of status epilepticus. In: Status Epilepticus: its Clinical Features and Treatment in Children and Adults. Shorvon S (Ed.). Cambridge University Press, Cambridge, UK (1994).
14. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 35, 27-34 (1994). •• Large study of prognostic factors for outcome in status epilepticus (SE), finding etiology as the key determinant. Duration of SE was significant if under 1 h, not beyond.
15. Schomer DL. Focal status epilepticus and epilepsia partialis continua in adults and children. Epilepsia 34(Suppl. 1), S29-S36 (1993).
16. Simon R, Pellock JM, DeLorenzo RJ. Acute morbidity and mortality of status epilepticus. In: Epilepsy: a Comprehensive Textbook. Engel J, Pedley TA (Eds). Lippincott-Raven Publishers, PA, USA (1997).
17. Drislane FW, Blum AS, Schomer DL. Focal status epilepticus: clinical features and significance of different EEG patterns. Epilepsia 40, 1254-1260 (1999).
18. Belafsky MA, Carwille S, Miller P, Waddell G, Boxley-Johnson J, Delgado-Escueta AV. Prolonged epileptic twilight states: continuous recordings with nasopharyngeal electrodes and videotape analysis. Neurology 28, 239-245 (1978).
19. Engel J, Ludwig BI, Fetell M. Prolonged partial complex status epilepticus: EEG and behavioral observations. Neurology 28, 863-869 (1978).
20. Treiman DM, Delgado-Escueta AV. Complex partial status epilepticus. In: Status Epilepticus. (Advances in Neurology; Vol. 34). Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ (Eds). Raven Press, NY, USA (1983).
21. Cockerell OC, Walker MC, Sander JWAS, Shorvon SD. Complex partial status epilepticus: a recurrent problem. J. Neurol. Neurosurg. Psychiatry 57, 835-837 (1994).
22. Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol. 6, 329-339 (2007).
23. Shorvon S, Walker M. Status epilepticus in idiopathic generalized epilepsy. Epilepsia 46(Suppl. 9), 73-79 (2005). • Reviewed SE in largely genetic, primary generalized epilepsy syndromes. Manifestations were varied; most cases had benign outcomes.
24. Thomas P, Beaumanoir A, Genton P, Dolisi C, Chatel M. 'De novo' absence status of late onset: report of 11 cases. Neurology 42, 104-110 (1992).
25. Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 61, 1066-1073 (2003). •• Mortality in nonconvulsive SE (NCSE) can be substantial and is associated with etiology, degree of mental status impairment and concomitant medical complications.
26. Tomson T, Lindbom U, Nilsson BY. Nonconvulsive status epilepticus in adults: thirty-two consecutive patients from a general hospital population. Epilepsia 33, 829-835 (1992).
27. Kaplan PW. Nonconvulsive status epilepticus. Semin. Neurol. 16, 33-40 (1996).
28. Treiman DM, Walton NY, Kendrick C. A progressive sequence of electrographic changes during generalized convulsive status epilepticus. Epilepsy Res. 5, 49-60 (1990).
29. Drislane FW, Schomer DL. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res. 19, 111-121 (1994).
30. Treiman DM, Meyers PD, Walton NY et al. A comparison of four treatments for generalized convulsive status epilepticus. N. Engl. J. Med. 339, 792-798 (1998). •• Multicenter randomized controlled trial comparing diazepam plus phenytoin, lorazepam, phenytoin alone and phenobarbital in the treatment of generalized convulsive SE (GCSE); found that intravenous lorazepam, 0.1 mg/kg, was the best initial treatment (at least compared with phenytoin alone).
31. DeLorenzo RJ, Waterhouse EJ, Towne AR et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 39, 833-840 (1998). • Demonstrated persistent electrographic seizure activity (at least intermittently) in 48% of patients after apparent control of GCSE, and 14% were in NCSE. Advocated use of EEG monitoring after treatment of SE.
32. Towne AR, Waterhouse EJ, Boggs JG et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 54, 340-345 (2000). •• Study of EEG monitoring in 236 comatose patients without any clinical signs of seizure activity, demonstrating NCSE in 8% of patients.
33. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 62, 1743-1748 (2004).
34. So EL, Ruggles KH, Ahmann PA, Trudeau SK, Weatherford KJ, Trenerry MR. Clinical significance and outcome of subclinical status epilepticus in adults. J. Epilepsy 8, 11-15 (1995).
35. Jagoda A, Riggio S. Refractory status epilepticus in adults. Ann. Emerg. Med. 22, 1337-1348 (1993).
36. Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 42, 380-386 (2001). • Found no significant differences between propofol and midazolam in clinical or electrographic seizure control in a small population with refractory SE (RSE), but propofol was associated with more mortality among more sick patients.
37. Towne AR, Garnett LK, Waterhouse RJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology 60, 332-334 (2003).
38. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch. Neurol. 59, 205-210 (2002).
39. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J. Neurol. Neurosurg. Psychiatry 76, 534-539 (2005).
40. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia 37, 863-867 (1996). • Largest series of pentobarbital treatment for RSE. Relapse of SE predicted a poor outcome; hypotension was common but manageable.
41. Osorio I, Reed RC. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin. Epilepsia 30, 464-471 (1989).
42. Yaffe K, Lowenstein DH. Prognostic factors for pentobarbital therapy for refractory generalized status epilepticus. Neurology 43, 895-900 (1993).
43. Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR. Very-high-dose phenobarbital for refractory status epilepticus in children. Neurology 38, 1035-1040 (1988).
44. Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia 48, 478-483 (2007).
45. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 55, 722-724 (2000).
46. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 67, 340-342 (2006). • Compared valproate and phenytoin in a small sample of GCSE patients; seizures were interrupted in 66% of the valproate group versus 42% in the phenytoin group.
47. Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 16, 527-532 (2007).
48. Olsen KB, Tauboll E, Gjerstad L. Valproate is an effective, well-tolerated drug for the treatment of status epilepticus/serial attacks in adults. Acta Neurol. Scand. Suppl. 187, 51-54 (2007).
49. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 8, 651-654 (2006).
50. Ramael S, Daoust A, Otoul C et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47, 1128-1135 (2006).
51. Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav. 12, 477-480 (2008).
52. Rupprecht S, Franke K, Fitzek S, Witte OW, Hagemann G. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res. 73, 238-244 (2007).
53. Farooq MU, Naravetia B, Majid A, Gupta R, Pysh JJ, Kassab MY. IV levetiracetam in the management of non-convulsive status epilepticus. Neurocrit. Care 7, 36-39 (2007).
54. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 43, 483-488 (1993).
55. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 814, 179-185 (1998).
56. A receptors. J. Neurosci. 17, 7532-7540 (1997).
57. Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J. Clin. Neurophysiol. 12, 326-342 (1995).
58. Chen JWY, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 5, 246-256 (2006).
59. Bleck TP. Management approaches to prolonged seizures and status epilepticus. Epilepsia 40(Suppl. 1), S59-S63 (1999).
60. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit. Care Med. 20, 483-488 (1992).
61. Parent JM, Lowenstein DH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 44, 1837-1840 (1994).
62. Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol. Sci. 23, 177-182 (2002).
63. Lowenstein DH, Alldredge BK. Status epilepticus. N. Engl. J. Med. 338, 970-976 (1998).
64. Rossetti AO, Reichart MD, Schaller M, Despland P, Bogousslavsky J. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 45, 757-763 (2004). • Retrospective study which found that propofol administered with clonazepam or phenytoin was effective in aborting approximately two-thirds of episodes of RSE.
65. Rasmussen PA, Yang Y, Ruteki PA. Propofol inhibits epileptiform activity in rat hippocampal slices. Epilepsy Res. 25, 169-175 (1996).
66. Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 39, 18-26 (1998).
67. Parke TJ, Stevens JE, Rice AS et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 305, 613-616 (1992).
68. Cremer OL, Moons KG, Bouman EAC, Kruijswijk JE, de Smet AMGA, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 357, 117-118 (2001).
69. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 29, 1417-1425 (2003).
70. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia 43, 146-153 (2002). •• Meta-analysis of 28 studies on treatment of RSE, which found that pentobarbital led to fewer SE relapses but more hypotension than midazolam or propofol. Treatment targeted to produce more EEG background suppression was more effective than other regimens but was associated with an increased risk of hypotension.
71. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch. Neurol. 62, 1698-1702 (2005). • Found that outcome in RSE was independent of antiepileptic or anesthetic agents used or the extent of EEG suppression, suggesting that etiology remains the prime determinant of outcome.
72. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 40, 759-762 (1999).
73. Walker MC, Howard RS, Smith SJ, Miller DH, Shorvon SD, Hirsch NP. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q. J. Med. 89, 913-920 (1996).
74. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 57, 1036-1042 (2001).
75. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology 51, 1765-1766 (1998).
76. Mazarati AM, Wasterlain CG. N-methyl-D-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci. Lett. 265, 187-190 (1999).
77. DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41(Suppl. 1), 40-44 (2000).
78. Petroff OA, Hyder F, Rothman DL, Mattson RH. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 42, 543-548 (2001).
79. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41(Suppl. 1), 17-20 (2000).
80. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockage of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 31(Suppl. 1), 10-16 (2000).
81. Alexopoulos A, Lachhwani DK, Gupta A et al. Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis. Neurology 64, 567-570 (2005).
82. Ma X, Liporace J, O'Connor MJ, Sperling MR. Neurosurgical treatment of medically intractable status epilepticus. Epilepsy Res. 46, 33-38 (2001).
83. Ng YT, Bristol RE, Schrader DV, Smith KA. The role of neurosurgery in status epilepticus. Neurocrit. Care 7, 86-91 (2007).
84. Duane DC, Ng Y, Rekate HL, Chung S, Bodensteiner JB, Kerrigan JF. Treatment of refractory status epilepticus with hemispherectomy. Epilepsia 45, 1001-1004 (2004).
85. Piatt JH, Hwang PA, Armstrong DC, Becker LE, Hoffman HJ. Chronic focal encephalitis (Rasmussen syndrome): six cases. Epilepsia 29, 268-279 (1998).
86. Drislane FW. Evidence against permanent neurologic damage from nonconvulsive status epilepticus. J. Clin. Neurophysiol. 16, 323-331 (1999).
87. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch. Neurol. 61, 1254-1259 (2004).
88. Kaplan PW. Assessing the outcome in patients with nonconvulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. J. Clin. Neurophysiol. 16, 341-352 (1999).
89. Kaplan PW. Prognosis in nonconvulsive status epilepticus. Epileptic Disord. 2, 185-193 (2000).
90. Aganthonikou A, Panayiotopoulos CP, Giannakodimos S, Koutroumanidis M. Typical absence status in adults: diagnostic and syndromic considerations. Epilepsia 39, 1265-1276 (1998).
91. Guberman A, Cantu-Reyna G, Stuss D, Broughton R. Nonconvulsive generalized status epilepticus: clinical features, neuropsychological testing, and long-term follow-up. Neurology 36, 1284-1291 (1986).
92. Kaplan PW. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin. Electroencephalogr. 30, 1-4 (1999).
93. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 41, 887-894 (2000).
94. Panayiotopoulos CP, Agathonikou A, Sharoqi IA, Parker AP. Vigabatrin aggravates absences and absence status. Neurology 49, 1467 (1997).
95. Ettinger AB, Bernal OG, Andriola MR et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 40, 1159-1162 (1999).
96. Shorvon S. The management of status epilepticus. J. Neurol. Neurosurg. Psychiatry 70(Suppl. 2), II22-II27 (2001).
97. Williamson PD. Complex partial status epilepticus. In: Epilepsy: a Comprehensive Textbook. Engel J, Pedley TA (Eds). Lippincott-Raven Publishers, PA, USA (1997).
98. Fagan KJ, Lee SI. Prolonged confusion following convulsions due to generalized nonconvulsive status epilepticus. Neurology 40, 1689-1694 (1990).
99. Drislane FW, Schomer DL. Anticonvulsant medication use in patients with continuous epileptiform discharges. Clin. Neuropharmacol. 17, 165-174 (1994).
100. Thomas P, Zifkin B, Migneco O, Lebrun C, Darcourt J, Andermann F. Nonconvulsive status epilepticus of frontal origin. Neurology 52, 1174-1183 (1999).
101. Kaplan PW. Nonconvulsive status epilepticus in the emergency room. Epilepsia 37, 643-650 (1996).